ARGYCE LLC
Patent Owner
Stats
- 13 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Jun 14, 2016 most recent publication
Details
- 13 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 308 Total Citation Count
- Jun 07, 1995 Earliest Filing
- 1 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
8716270 Polymorphic and amorphous salt forms of squalamine dilactateJun 23, 11May 06, 14[A61K, C07J]
7981876 Polymorphic and amorphous salt forms of squalamine dilactateApr 25, 06Jul 19, 11[A61K, C07J]
7728157 Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterolsMar 21, 05Jun 01, 10[C07J]
7074778 Asthma associated factors as targets for treating atopic allergies including asthma and related disordersDec 11, 00Jul 11, 06[A61K]
6933383 Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterolsOct 11, 02Aug 23, 05[C07J]
6610866 Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compoundsApr 12, 01Aug 26, 03[C07C, C07J]
6596712 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalitiesMar 12, 01Jul 22, 03[A61K]
6262283 Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compoundsDec 05, 97Jul 17, 01[C07J]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
6962909 Treatment of neovascularization disorders with squalimineExpiredNov 02, 01Nov 08, 05[A61K, C07C]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.